Hand Hygiene Surveillance Start-Ups Look To Clean Up Health Care-Acquired Infections

If health care workers washed their hands before and after any patient contact, health care-acquired infection rates could be reduced by 50%. There is a great need for electronic tools that can automatically capture compliance behavior without disrupting workflow. We profile four health care information technology start-ups that are answering this call: BioVigil Systems, GLANTA, HanGenix and Proventix.

Health care-acquired infections (HCAIs) represent the most frequent health care adverse event, and are a serious and growing public health problem worldwide. According to World Health Organization (WHO) data, HCAI prevalence was estimated at 7.6% for all hospital admissions in high-income countries from 1995 to 2010, and at well above 20% in developing countries, although scant data are available for the latter. There is clear evidence that hundreds of millions of patients are affected every year worldwide with surgical site, bloodstream and urinary tract infections, pneumonia and other often-deadly illnesses. Nearly 1.7 million HCAIs are diagnosed annually in the US, according to the Centers for Disease Control & Prevention (CDC), impacting one out of every 20 admitted patients. Such infections increase the average length of stay by 7.4 to 9.4 days and lead to approximately 100,000 deaths a year – representing the fourth-leading cause of death overall. The economic burden of HCAIs is substantial and increasing: ranging between $20 and $45 billion in direct medical costs annually in the US, according to the CDC (at an average of $20,000 per case) – a staggering bill for a health care system already in critical condition.

According to William Quirk, managing director and senior research analyst at Piper Jaffray, HCAIs have been gaining increased attention worldwide...

Welcome to Medtech Insight

Create an account to read this article

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

BD Sees $90M Tariff Hit In Q4; 2026 Impact Reduced To $275M

 
• By 

BD raised its adjusted earnings per share guidance midpoint by $0.18 to a range of $14.30 to $14.45, representing growth of about 9.4% at the midpoint – an increase of approximately 1.4% over prior guidance.

Warning Letters - July 2025

The US FDA posted three warning letters in July, covering medical supply kits, wearables and orthopedics.

Brazil’s Medtechs Look To Solutions After 50% US Tariff Hit Amid ‘Scenario Of Uncertainty’

 

Hopes that last-minute negotiations might exempt Brazil’s $300m medtech exports from the latest round of US tariffs have been dashed, leaving the industry braced for further market instability that countermeasures could trigger.